Leerink Partnrs Brokers Increase Earnings Estimates for THC

Tenet Healthcare Co. (NYSE:THC - Free Report) - Research analysts at Leerink Partnrs raised their Q3 2025 earnings estimates for Tenet Healthcare in a research note issued to investors on Tuesday, June 3rd. Leerink Partnrs analyst W. Mayo now forecasts that the company will post earnings per share of $2.28 for the quarter, up from their prior forecast of $2.17. The consensus estimate for Tenet Healthcare's current full-year earnings is $12.24 per share. Leerink Partnrs also issued estimates for Tenet Healthcare's Q4 2025 earnings at $3.02 EPS, Q3 2026 earnings at $2.91 EPS, Q4 2026 earnings at $3.69 EPS, FY2026 earnings at $13.98 EPS and FY2027 earnings at $17.19 EPS.

Tenet Healthcare (NYSE:THC - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The company reported $4.36 EPS for the quarter, beating analysts' consensus estimates of $3.11 by $1.25. Tenet Healthcare had a net margin of 15.48% and a return on equity of 21.88%. The company had revenue of $5.22 billion during the quarter, compared to analyst estimates of $5.15 billion. During the same period last year, the business earned $3.22 earnings per share. Tenet Healthcare's revenue was down 2.5% compared to the same quarter last year.

Other research analysts also recently issued reports about the stock. Wells Fargo & Company raised shares of Tenet Healthcare from an "equal weight" rating to an "overweight" rating and raised their price target for the company from $150.00 to $195.00 in a report on Thursday, May 29th. Barclays lifted their target price on shares of Tenet Healthcare from $171.00 to $215.00 and gave the company an "overweight" rating in a research report on Monday, June 2nd. Bank of America lifted their target price on shares of Tenet Healthcare from $165.00 to $180.00 and gave the company a "buy" rating in a research report on Wednesday, May 14th. The Goldman Sachs Group lifted their target price on shares of Tenet Healthcare from $134.00 to $154.00 and gave the company a "neutral" rating in a research report on Monday, May 5th. Finally, Robert W. Baird reiterated a "neutral" rating and set a $137.00 target price (down from $153.00) on shares of Tenet Healthcare in a research report on Tuesday, April 15th. Four analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $180.18.

Tenet Healthcare Price Performance

NYSE:THC traded down $0.48 during trading hours on Friday, hitting $171.36. The stock had a trading volume of 1,351,072 shares, compared to its average volume of 1,523,627. The company has a 50 day simple moving average of $144.43 and a two-hundred day simple moving average of $137.09. The company has a debt-to-equity ratio of 2.25, a current ratio of 1.78 and a quick ratio of 1.70. Tenet Healthcare has a one year low of $109.82 and a one year high of $174.14. The firm has a market capitalization of $15.92 billion, a price-to-earnings ratio of 5.32, a P/E/G ratio of 1.02 and a beta of 1.65.

Insider Buying and Selling

In related news, EVP Paola M. Arbour sold 6,461 shares of Tenet Healthcare stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $160.20, for a total value of $1,035,052.20. Following the transaction, the executive vice president now directly owns 27,848 shares of the company's stock, valued at $4,461,249.60. The trade was a 18.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director J Robert Kerrey sold 9,525 shares of Tenet Healthcare stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $125.43, for a total transaction of $1,194,720.75. Following the completion of the transaction, the director now directly owns 27,378 shares in the company, valued at approximately $3,434,022.54. The trade was a 25.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 63,646 shares of company stock valued at $10,041,025 over the last three months. 0.81% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in THC. Strs Ohio purchased a new position in Tenet Healthcare during the 1st quarter valued at $1,550,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Tenet Healthcare by 4.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 276,969 shares of the company's stock valued at $37,252,000 after purchasing an additional 12,914 shares during the period. Empowered Funds LLC increased its position in Tenet Healthcare by 19.6% during the 1st quarter. Empowered Funds LLC now owns 154,754 shares of the company's stock valued at $20,814,000 after purchasing an additional 25,323 shares during the period. United Services Automobile Association purchased a new position in Tenet Healthcare during the 1st quarter valued at $821,000. Finally, Fred Alger Management LLC purchased a new position in Tenet Healthcare during the 1st quarter valued at $2,652,000. 95.44% of the stock is owned by hedge funds and other institutional investors.

Tenet Healthcare Company Profile

Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies.